Get the Stockscreener App
21.39
2.05%
0.43
After Hours:
21.31
-0.08
-0.37%
Catalyst Pharmaceuticals Inc stock is traded at $21.39, with a volume of 959.62K.
It is up +2.05% in the last 24 hours and up +9.58% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$20.96
Open:
$21.21
24h Volume:
959.62K
Relative Volume:
0.66
Market Cap:
$2.62B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
18.13
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+1.81%
1M Performance:
+9.58%
6M Performance:
-8.78%
1Y Performance:
-0.33%
1-Day Range:
$21.04
$21.52
1-Week Range:
$20.66
$21.55
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.39 | 2.57B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Applying Elliott Wave Theory to Catalyst Pharmaceuticals Inc.July 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
Why Catalyst Pharmaceuticals Inc. stock is favored by pension fundsJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsMarket Trend Review & Community Verified Watchlist Alerts - newser.com
Is Catalyst Pharmaceuticals Inc. stock bottoming outMarket Risk Report & Community Trade Idea Sharing Platform - newser.com
Catalyst Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Chart Watch & Daily Market Momentum Tracking - newser.com
Price momentum metrics for Catalyst Pharmaceuticals Inc. explained2025 Price Action Summary & Safe Swing Trade Setup Alerts - newser.com
Can Catalyst Pharmaceuticals Inc. hit a new high this monthPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - newser.com
Will Catalyst Pharmaceuticals Inc. (CN2) stock sustain uptrend momentumMarket Trend Report & High Return Trade Guides - newser.com
How rising interest rates impact Catalyst Pharmaceuticals Inc. stockMarket Activity Summary & AI Optimized Trading Strategy Guides - newser.com
Is Catalyst Pharmaceuticals Inc. (CN2) stock attractive post correction2025 Dividend Review & Stepwise Trade Execution Plans - newser.com
Why global investors buy Catalyst Pharmaceuticals Inc. (CN2) stockQuarterly Profit Review & Verified Momentum Watchlists - newser.com
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elsbernd Brian | Chief Compliance/Legal Officer |
Sep 08 '25 |
Sale |
20.30 |
30,000 |
609,000 |
271,039 |
0.00%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):